Skip to main content
Clinical Trials/NCT07569003
NCT07569003RecruitingNot Applicable

Preliminary Study: Effect of Nutrition Therapy on Prealbumin and IGF-1 Level in Severe Malnutrition Under Five Years Old With Chronic Cholestasis

Indonesia University1 site in 1 country15 target enrollmentStarted: April 6, 2026Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
15
Locations
1

Study Overview

Brief Summary

The goal of this clinical trial is to learn if a high-energy liquid diet improves the nutritional status of children with chronic cholestasis (a liver condition that blocks bile flow). Researchers want to see if this diet helps children who are malnourished.

The main questions the study aims to answer are:

  • Does the liquid diet raise the level of prealbumin (a marker of nutrition) in the blood?
  • Does the liquid diet raise the level of Insulin-like Growth Factor-1 (IGF-1) (a hormone that helps growth) in the blood?

Participants will:

  • Consume a high-energy liquid diet for 14 days.
  • Give blood samples at the start and at the end of the 2-week study.
  • Keep a daily record of what they eat and drink in a food diary. Researchers will compare the blood test results from the start and the end of the study to see if the liquid diet works to improve the children's prealbumin and IGF-1 levels. This study is important to help children with liver problems grow better and stay healthy.

Detailed Description

The study evaluates the effect of nutritional therapy on prealbumin levels and insulin-like growth factor-1 (IGF-1) levels in malnourished children with chronic cholestasis aged 3-59 months (primary outcome) and diet tolerance, nutritional status, and medical condition (secondary outcomes).

Prealbumin and IGF-1 levels are measured as primary outcomes at baseline (day 0) and at day 15. Diet tolerance is assessed using the Bristol Stool Chart, a daily vomiting record throughout the 14-day intervention period, and allergic reactions. The frequency of defecation and consistency of each stool are documented. Allergic reactions are also monitored during the intervention period, including symptoms such as fever, erythematous rash, pruritus, and respiratory symptoms such as shortness of breath. The onset, duration, and severity of these symptoms are recorded.

Vomiting is evaluated as the number of episodes per day over the 14-day intervention period, and the volume of each episode is recorded. Only vomiting attributable to diet intolerance is included in the analysis, while episodes related to other causes, such as coughing or crying, are excluded.

Anthropometric parameters, including weight, height, mid-upper arm circumference, and other relevant measurements, are assessed on day 0, day 8, and day 15 to monitor changes in nutritional status.

Medical conditions during the study period are closely monitored, including underlying diseases, comorbidities, and intercurrent illnesses (e.g., respiratory or gastrointestinal infections). Clinical changes, hospitalizations, medication use, and any complications occurring during the intervention are recorded to evaluate their potential impact on nutritional status and study outcomes.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
— to 5 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Children under 5 years old
  • Diagnosed with chronic cholestasis and severe malnutrition
  • Parental/guardian informed consent
  • Willingness to use a nasogastric tube (NGT) if indicated
  • Covered by national health insurance or other insurance

Exclusion Criteria

  • Comorbidities (heart failure, chronic kidney disease, HIV)
  • Severe acute infections (acute gastroenteritis, dengue fever, pneumonia)
  • Post-liver transplant
  • Post-Kasai portoenterostomy (jaundice-free)
  • Currently exclusively breastfeeding
  • Use of steroids or NSAIDs within two weeks prior to the study.
  • Receiving a transfusion of whole blood, fresh frozen plasma, or platelets within one week prior to the study

Arms & Interventions

Nutrition Therapy Group

Experimental

Nutrition therapy

Intervention: Nutrition Therapy (Other)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

dr. Tri Faranita, MKed(Ped), SpA

Pediatrician, Fellow in Pediatric Nutrition and Metabolic Diseases

Indonesia University

Study Sites (1)

Loading locations...

Similar Trials